Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tunlametinib by Binjiang Pharma for Metastatic Colorectal Cancer: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData,...
Tunlametinib by Binjiang Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Tunlametinib by Binjiang Pharma for Solid Tumor: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tunlametinib by Binjiang Pharma for Metastatic Melanoma: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase III for Metastatic Melanoma. According to GlobalData, Phase...
Tunlametinib by Binjiang Pharma for Metastatic Colorectal Cancer: Likelihood of Approval
Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData,...